Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Akio Moriya"'
Autor:
Yasuto Takeuchi, Kazuhiro Nouso, Shin‐ichi Fujioka, Kazuya Kariyama, Haruhiko Kobashi, Shuji Uematsu, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Shinichiro Nakamura, Kazuhisa Yabushita, Tatsuya Kikuchi, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17559-17568 (2023)
Abstract Background and Aims The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it now considered the first‐line systemic chemotherapy agent fo
Externí odkaz:
https://doaj.org/article/1ea116a95b5e4f80b663222db653b559
Autor:
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 4, Pp 851-866 (2020)
Abstract Introduction Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings. We aimed to evaluate the safety and
Externí odkaz:
https://doaj.org/article/55849d97b2c94d3998b61e259f39e8f7
Publikováno v:
JGH Open, Vol 4, Iss 4, Pp 698-706 (2020)
Abstract Background and Aim A low hepatitis B surface antigen (HBsAg) level is reported to be predictive of future HBsAg seroclearance. A hospital‐based cohort study was conducted to clarify the clinical features of patients with low HBsAg levels a
Externí odkaz:
https://doaj.org/article/7157aebb74a14174b9a6bbe27f4e1971
Autor:
Atsushi Imagawa, Hidenori Hata, Morihito Nakatsu, Akihiro Matsumi, Eijiro Ueta, Kozue Suto, Hiroyuki Terasawa, Hiroyuki Sakae, Keiko Takeuchi, Manabu Fujihara, Hitomi Endo, Hisae Yasuhara, Shinichi Ishihara, Hiromitsu Kanzaki, Hideki Jinno, Hidenori Kamada, Eisuke Kaji, Akio Moriya, Masaharu Ando
Publikováno v:
Endoscopy International Open, Vol 03, Iss 01, Pp E2-E6 (2015)
Background and study aims: Propofol administration via a target-controlled infusion system with bispectral index monitoring (BIS/TCI system) is expected to prevent complications from sedation during complex and long endoscopic procedures. We evaluate
Externí odkaz:
https://doaj.org/article/6b1b678e97c3439bb083095cba3a697e
Autor:
Hidenori Toyoda, Satoshi Yasuda, Akio Moriya, Ei Itobayashi, Haruki Uojima, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Toru Ishikawa, Shigeru Mikami, Atsushi Hiraoka, Kunihiko Tsuji, Tsunekazu Oikawa, Akihito Tsubota, Akito Nozaki, Makoto Chuma, Hiroshi Abe, Toshihide Shima, Takashi Kumada, Junko Tanaka
Publikováno v:
Journal of Infection and Chemotherapy. 28:1231-1234
With the increase in the number of patients with sustained virologic response (SVR) in whom hepatitis C virus (HCV) was eradicated by the anti-HCV therapy, there are now many individuals in whom serum HCV RNA is absent despite positive serum HCV anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170f643e04420e8c57346a95037f1302
https://doi.org/10.1016/j.jiac.2022.04.024
https://doi.org/10.1016/j.jiac.2022.04.024
Autor:
Masaki, Kyoko Oura, Asahiro Morishita, Takushi Manabe, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Chikara Ogawa, Akio Moriya, Tomonori Senoo, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Takashi Himoto, Tsutomu
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3243
Although there have been advances in the prevention and diagnosis of hepatocellular carcinoma (HCC) in recent years, many HCC patients are still diagnosed with advanced stage. Systemic therapy is indicated for unresectable HCC (uHCC) with major vascu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::4d2a00f84c62dc2b578789d9caf9fe00
Publikováno v:
Kanzo. 62:663-666
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::210b24c4a7ce3a0359300a0e096b9b5b
https://doi.org/10.2957/kanzo.62.663
https://doi.org/10.2957/kanzo.62.663
Autor:
Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki, Tetsuji Takayama
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES.
Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c41ad1ee73c11d1e4904c023c82346
https://pubmed.ncbi.nlm.nih.gov/36214071
https://pubmed.ncbi.nlm.nih.gov/36214071
Autor:
Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tingting Shi, Takashi Himoto, Miwa Tatsuta, Akio Moriya, Tomonori Senoo, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Masafumi Ono, Tsutomu Masaki
Publikováno v:
Hepatology international.
Background This retrospective, multicenter study evaluated the effect of pemafibrate treatment on liver function and fibrosis by liver function tests (LFTs) and various fibrotic biomarkers including FibroScan in non-alcoholic fatty liver disease (NAF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9196425592efbb7ec228bc522da6514e
https://pubmed.ncbi.nlm.nih.gov/36583842
https://pubmed.ncbi.nlm.nih.gov/36583842
Autor:
Naoki Hotta, Toshihide Shima, Norio Itokawa, Akio Moriya, Katsuhiko Iwakiri, Takashi Kumada, Makoto Nakamuta, Chisa Kondo, Shin Maeda, Toru Ishikawa, Shigeru Mikami, Taeang Arai, Shinichi Fujioka, Atsushi Hiraoka, Shinya Fukunishi, Makoto Chuma, Yasuhito Tanaka, Hidenori Toyoda, Hironao Okubo, Haruki Uojima, Noritomo Shimada, Takeshi Okanoue, Takehiro Akahane, Takuya Genda, Joji Tani, Shintaro Ogawa, Koichi Takaguchi, Tsunamasa Watanabe, Masanori Atsukawa, Hiroshi Abe, Hiroki Ikeda, Chikara Ogawa, Akihito Tsubota, Asahiro Morishita, Toru Asano, Yoshihiko Tachi, Akito Nozaki, Tadashi Ikegami
Publikováno v:
Hepatology International. 14:225-238
Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. In a phase III trial in Japan, treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37398fdeeaeb93023154fb7f4e4d5a96
https://doi.org/10.1007/s12072-020-10019-z
https://doi.org/10.1007/s12072-020-10019-z